Cargando…
External Validation of the BRAVO Diabetes Model Using the EXSCEL Clinical Trial Data
INTRODUCTION: We have developed the Building, Relating, Assessing, and Validating Outcomes (BRAVO) diabetes model, an individual-level, discrete-time microsimulation model specifically designed for type 2 diabetes (T2D) management. This study aims to validate the model’s performance when populated e...
Autores principales: | Shao, Yixue, Shao, Hui, Fonseca, Vivian, Shi, Lizheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363088/ https://www.ncbi.nlm.nih.gov/pubmed/37432547 http://dx.doi.org/10.1007/s13300-023-01441-1 |
Ejemplares similares
-
Effect of once‐weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial
por: van der Aart‐van der Beek, Annemarie B., et al.
Publicado: (2020) -
Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL
por: Idzerda, Nienke M. A., et al.
Publicado: (2020) -
Comment on Segar et al. Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. Diabetes Care 2019;42:2298–2306
por: Shao, Hui, et al.
Publicado: (2020) -
Exacerbation of financial burden of insulin and overall glucose‐lowing medications among uninsured population with diabetes
por: Lin, Yilu, et al.
Publicado: (2023) -
Effect of Once‐Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial
por: Mentz, Robert J., et al.
Publicado: (2018)